Fixation group as effective as non-fixation groups in terrible triad injuries of elbow, reveals study

No significant differences in outcomes between fixation and non-fixation groups in terrible triad injuries of elbow reveals a study published in the BMC Surgery.

The ideal treatment of terrble triad injuries and whether fixation of coronoid process fractures is needed or not are still debated. Therefore, we aimed to investigate if terrible triad injuries necessitate coronoid fracture fixation and evaluate if non-fixation treatments have similar efficacies and outcomes as fixation treatments in cases of terrible triad injuries. From August 2011 to July 2020, 23 patients with acute terrible triad injuries without involvement of the anteromedial facet of the coronoid process were included to evaluate the postoperative clinical and radiological outcomes (minimum follow-up of 20 months). According to the preoperative height loss evaluation of the coronoid process and an intraoperative elbow stability test, seven patients underwent coronoid fracture fixation, and the other eight patients were treated conservatively. The elbow range of motion (ROM), Mayo Elbow Performance Score (MEPS), and modified Broberg-Morrey score were evaluated at the last follow-up. In addition, plain radiographs were reviewed to evaluate joint congruency, fracture union, heterotopic ossification, and the development of arthritic changes. Results: At the last follow-up, the mean arcs of flexion-extension and supination-pronation values were 118.2° and 146.8° in the fixation group and 122.5° and 151.3° in the non-fixation group, respectively. The mean MEPSs were 96.4 in the fixation group (excellent, nine cases; good, tow cases) and 96.7 in the non-fixation group (excellent, ten cases; good, two cases). The mean modified Broberg-Morrey scores were 94.0 in the fixation group (excellent, sevev cases; good, four cases) and 94.0 in the non-fixation group (excellent, ten cases; good, tow cases). No statistically significant differences in clinical scores and ROM were identified between the two groups. However, the non-fixation group showed a significantly lower height loss of the coronoid process than the fixation group (36.3% versus 54.5%). There were no significant differences in clinical outcomes between the fixation and non-fixation groups in terrible triad injuries.

Reference:

Ahn, YS., Woo, SH., Kim, S. et al. Does the coronoid fracture in terrible triad injury always need to be fixed?. BMC Surg 24, 125 (2024). https://doi.org/10.1186/s12893-024-02394-3

Keywords:

No, significant, differences, outcomes, between, fixation, non-fixation, group, terrible, triad, injuries, elbow, study, Coronoid fracture, Height loss ratio, Intraoperative elbow stability test, Outcomes, Ahn, YS., Woo, SH., Kim, S, BMC Surgery

Powered by WPeMatico

Cancer Pain Guidelines evaluation stresses on safe opioid practice and patient feedback systems, claims study

Cancer pain is the most distressing symptom in a patient’s life, with fear of unrelieved pain sometimes exceeding the patient’s fear of death.

Recently published research paper evaluates the quality of cancer pain guidelines and examines the inclusion of safe opioid practice. It highlights the distressing nature of cancer pain and emphasizes the concept of ‘total pain management’ that incorporates various modalities and safe opioid practices to improve the quality of life for cancer patients. The paper discusses the global challenge of limited access to opioids for cancer pain management and the looming opioid crisis due to misuse and abuse. It emphasizes the need for individualized protocols for different types of cancer pain and the importance of addressing end-of-life care pain management. The methodology involves evaluating the guidelines using the AGREE II and ADAPTE tools, and the primary outcome is to assess the quality of cancer pain guidelines. The review included 14 guidelines, and quality assessment was based on various domains such as rigour of development, applicability, and editorial independence. The study demonstrates good inter-rater reliability and identifies eight high-quality guidelines, with four specific guidelines deemed to be of the highest quality. The comprehensive assessment of the guidelines indicates that safe opioid practices and patient feedback are incorporated into the guidelines, contributing to their quality attributes. Overall, the paper provides a detailed evaluation of cancer pain guidelines and emphasizes the importance of safe opioid practices in cancer pain management.

Researchers  concluded that combined AGREE II and ADAPTE identified eight quality guidelines for quality evaluation, of which four cancer pain guidelines (MOHM, NCCN, NCEC-NCG, and WHO) were evaluated to be of the highest quality. All the evaluated guidelines inherently incorporated safe opioid practice and patient feedback systems, which are quality attributes.

Reference –

Thota, Raghu S.; Ramkiran, Seshadri1; Singh, Sarita2; Damani, Anuja3; Wajekar, Anjana S.4; Koyyalagunta, Lakshmi5. A systematic review and quality analysis of cancer pain guidelines. Indian Journal of Anaesthesia 67(12):p 1051-1060, December 2023. | DOI: 10.4103/ija.ija_325_23

Powered by WPeMatico

Home-monitoring tests lack satisfactory diagnostic accuracy to identify neovascular age-related macular degeneration:JAMA

A recent study found home-monitoring tests as a potential solution to reduce the burden of neovascular age-related macular degeneration (nAMD) on patients and healthcare systems. The study published in the Journal of American Medical Association evaluated three such tests and found that they may not be as effective as hoped.

This study assessed the diagnostic accuracy of three vision home-monitoring tests when compared to traditional hospital follow-up for detecting active nAMD. The tests evaluated were the KeepSight Journal (KSJ), the MyVisionTrack (mVT) app and the MultiBit (MBT) app. This research was conducted across six UK hospital eye clinics and included a total of 297 patients who were over 50 years, with at least one eye treated for active nAMD. The participants were asked to perform the home-monitoring tests weekly, with mVT and MBT scores automatically transmitted, while KSJ scores were returned to the research office every 6 months.

Despite the potential promise of these home-monitoring tools, the results were not very promising. The study highlighted that the estimated area under the receiver operating characteristic curve (AUROC) for all three tests was less than 0.6. None of the tests demonstrated satisfactory diagnostic accuracy for identifying active nAMD when compared to in-hospital ophthalmologist examination.

Of the 3 tests evaluated, only the KSJ summary score showed association with lesion activity. But, even this association was not strong enough to provide reliable detection of active nAMD. These findings have significant implications for the management of nAMD. While home-monitoring tests may offer convenience and reduce the burden on patients and caregivers, their limited accuracy points that they may not be suitable as standalone diagnostic tools.

The study illuminates the importance of continued research and innovation in the field of nAMD monitoring. While home-monitoring tests may not be ready for widespread clinical use, the ongoing advancements in technology and healthcare delivery may eventually lead to more effective solutions. The patients and clinicians must remain cautious and rely on the established methods for monitoring and managing nAMD. While the promise of home-monitoring tests remains, further research and extensive studies are needed to ensure their reliability and effectiveness in clinical practice.

Reference:

Hogg, R. E., Sivaprasad, S., Wickens, R., O’Connor, S., Gidman, E., Ward, E., Treanor, C., Peto, T., Burton, B. J. L., Knox, P., Lotery, A. J., Donnelly, M., Rogers, C. A., & Reeves, B. C. (2024). Home-Monitoring Vision Tests to Detect Active Neovascular Age-Related Macular Degeneration. In JAMA Ophthalmology. American Medical Association (AMA). https://doi.org/10.1001/jamaophthalmol.2024.0918

Powered by WPeMatico

In Preterm babies, Lung ultrasound scores useful to predict Bronchopulmonary dysplasia: Study

In a recent study published in the Pediatric Pulmonology unveiled the potential of lung ultrasound (LUS) as a rapid and effective method for evaluating preterm infants facing respiratory distress.

The study was conducted at an academic tertiary Neonatal Intensive Care Unit focused on infants younger than 32 weeks by bringing out LUS as a promising predictor for bronchopulmonary dysplasia (BPD) in preterm neonates.

This retrospective observational study encompassed 218 patients from the years 2018 to 2023, to understand the relationship between LUS scores within the first three days of life and critical respiratory outcomes. The lungs were divided into six regions with each assigned a score ranging from 0 to 3 points. The total score was obtained by summing these regional scores which proved to be an important indicator.

The key findings of study were;

Infants with the highest and lowest LUS scores within the initial three days expressed a significant association with the development of moderate-to-severe BPD (p < .001) with the area under the receiver operating characteristic (ROC) curve values from 0.684 to 0.913 and 0.647 to 0.902, respectively. High LUS scores were also linked to the requirement for mechanical ventilation (p < .001) despite no significant correlation found with the duration of mechanical ventilation.

The highest LUS scores within the first three days of life being sepsis and the presence of hemodynamically significant patent ductus arteriosus (hsPDA) emerged as significant risk factors.

This study establishes LUS scores as predictors of BPD and the need for invasive ventilation. These findings open possibilities for early intervention and personalized care strategies for the vulnerable preterm population by potentially reshaping the management of respiratory distress in neonatal intensive care units.

Reference:

Aliyev, F., Kayki, G., Annakkaya Kocyigit, T., İyigun, İ., & Yigit, S. (2023). Lung ultrasound scores within the first 3 days of life to predict respiratory outcomes. In Pediatric Pulmonology. Wiley. https://doi.org/10.1002/ppul.26804

Powered by WPeMatico

High blood urea nitrogen to serum albumin ratio may increase mortality risk in DM patients with CKD: Study

A recent study published in the recent edition of Nature Scientific Reports highlight on a critical aspect of managing critically ill patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). This retrospective study assessed the relationship between the Blood Urea Nitrogen to Serum Albumin Ratio (BAR) and mortality outcomes in this patient population.

After utilizing vast reservoir of the Medical Information Mart database Shizhen Liu and colleagues conducted a comprehensive analysis by enrolling a total of 1920 patients. These individuals suffered the dual burden of T2DM and CKD and were meticulously divided into three groups based on their BAR levels: BAR < 9.2, 9.2 ≤ BAR ≤ 21.3 and BAR > 21.3. The primary focus of the study was to elucidate the impact of BAR on 90-day mortality, while also exploring secondary outcomes such as the length of ICU stay, hospital mortality and 30-day mortality.

The key findings of the study were;

The patients with BAR levels exceeding 21.3 expressed significantly prolonged ICU stays and markedly elevated rates of 30-day and 90-day mortality when compared to their counterparts in lower BAR groups. Also, the cox regression analysis revealed a clear association between higher BAR levels and an augmented risk of 90-day mortality.

The adjusted hazard ratios (HR) from the regression models solidified the significance of BAR as a prognostic indicator. Even after accounting for various confounding factors like the age, comorbidities and severity of illness, the relationship between increased BAR levels and elevated mortality risk remained robust. The subgroup analyses underlined the consistency of these findings across different patient demographics and clinical scenarios by reinforcing the reliability of BAR as a predictive tool.

The gravity of these results was graphically depicted through Kaplan–Meier survival curve analysis that vividly portrayed the stark divergence in 90-day survival rates based on BAR levels. The individuals with BAR > 21.3 faced substantially lower survival probabilities by highlighting the critical importance of this marker in risk stratification and clinical decision-making. In conclusion, this study elucidates the potential of BAR as a simple yet invaluable prognostic tool in the management of T2DM patients with CKD in the intensive care unit (ICU).

Reference:

Liu, S., Qiu, C., Li, W., Li, X., Liu, F., & Hu, G. (2024). Blood urea nitrogen to serum albumin ratio as a new prognostic indicator in type 2 diabetes mellitus patients with chronic kidney disease. In Scientific Reports (Vol. 14, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1038/s41598-024-58678-4

Powered by WPeMatico

Bengaluru Hospital, Laparoscopic Surgeon Slapped Compensation for Negligence in Surgery

Bengaluru: A District Consumer Court in Bengaluru recently directed a General and Laparoscopic Surgeon and a city-based Hospital to pay Rs 90,000 as compensation to a patient, who underwent surgery at the facility. It was submitted by the patient that even after undergoing surgery for the fistula issue, he did not get any relief and had to seek treatment elsewhere.

“If the surgery had been conducted properly there would not have the problem and the pain of the complainant as asserted,” opined the consumer court while slapping the compensation on the doctor and the hospital.

The matter goes back to 2021 when the treating doctor conducted surgery on the patient at the treating hospital for a fistula in the anus as the patient had developed severe pain and oozing from the anal region and was suffering from unbearable pain and discomfort.

For the treatment including tests, consultation, surgery, post-operative care, medicines etc. the complainant had to spend around Rs 70,000. Allegedly, even after the surgery, he did not get any relief even after having medicines as prescribed, there was no improvement even after post-surgery with medication and rest and the same was not cured. 

The patient alleged that the treating doctor had assured that within 5 days post-surgery, he would recover completely. However, the pain did not subside and therefore, the complainant consulted another Doctor at Shridi Sai Hospital. The doctors at the second hospital conducted the required tests and ascertained that the “Left Anterior Perianal Low Level Fistula” had not been removed through the surgery conducted.

Further, the patient was informed that he had to pay another Rs 75,000 to Rs 90,000 for the next surgery. Since the complainant was not able to spend that much of the amount he intended to make an appointment with the treating doctor. However, when he did not get an appointment, he secured an appointment through a fake name. Allegedly, the doctor did not hear the problem and a scuffle broke out and a complaint was lodged on 29.06.2021. Following this, the patient took Ayurvedic treatment at Sri. Dhanvantri Ayurveda Hospital, Bangalore.

On the other hand, the doctor and the hospital submitted that the patient had signed the consent form for the surgery and the said disease cannot be completely cured even after the surgery. It was submitted that it depends on diet habits, follow-up treatment and maintaining the food prescribed. It was submitted that the disease concerned is not permanently curable.

Further, it was submitted that the doctor conducted the prescribed procedure as a prudent medical professional would do in the facts and circumstances of the case. 

However, while considering the matter, the consumer court opined that there was a deficiency in service and the patient was partly entitled to the relief sought.

The consumer court took note of the acknowledgement given by the police regarding the complaint, in which it was alleged that even after the surgery the complainant had not been completely cured and he approached Shridi Sai Hospital, where the doctor gave a report that proper treatment was not given. 

Apart from this, the consumer court also perused the prescription obtained from Shridi Sai Hospital and noted “On perusal of the same it appears that the complainant had obtained treatment at Shridi Sai hospital on 26.05.2021 and the scanning and diagnostic report issued by Imaging and diagnostic centre dated: 26.05.2021 indicates that the complainant had the problem of “Left Anterior Perianal Low Level Fistula”.”

The complainant also produced a treatment charges receipt issued by the Ayurveda Hospital, where “Kshara Sutra” treatment procedure was given and the patient was kept under observation for one day. The Commission noted that the complainant paid a total bill of Rs 49,550 at the Ayurveda Hospital.

Noting this, the consumer court observed,

“We feel that itself indicates that the complainant had the problem and with the surgery by opposite party No. 1 the Fistula problem of the complainant has not been removed completely. If the surgery had been conducted properly there would not have the problem and the pain of the complainant as asserted. Further, it appears to us that nobody would visit and get admitted to the hospital post-surgery as the complainant did without any problem.”

The consumer court further noted that the treating hospital and doctor did not argue that the medical bills and documents issued by the Ayurveda Hospital were concocted. 

Therefore, opining that there was medical negligence and deficiency on the part of the treating doctor and hospital, the Commission noted,

“Hence, we feel there was negligence on the part of opposite party No. 1 in conducting the surgery properly. The facts of the case in the cited judgment is entirely differed from the facts of the case in hand thereby the same is not applicable. Hence, for the above said reasons, there is deficiency of service on the part of opposite party No. 1 and as opposite party No. 1 has conducted the surgery at opposite party No. 2 hospital, we feel there is deficiency of service on the part of opposite party No. 2 also.”

By considering the pain and suffering undergone by the patient and the extra expenses at Ayurveda hospital, the Commission opined that the complainant was entitled to a sum of Rs 60,000, another Rs 20,000 for the mental agony and suffering that he had to undergo and Rs 10,000 towards litigation cost.

Accordingly, the Commission ordered, “Complaint is allowed in part. The Opposite Party No. 1 & 2 are jointly and severally liable to pay a sum of Rs.60,000/- towards extra expenses incurred by the complainant in the form of damages and a sum of Rs.20,000/- towards mental agony and sufferings undergone and a sum of Rs.10,000/- towards litigation cost.”

To view the consumer court order, click on the link below:

https://medicaldialogues.in/pdf_upload/bengaluru-consumer-court-235670.pdf

Also Read: Faulty fissures operation: Bengaluru Hospital, Doctor slapped compensation

Powered by WPeMatico

NMC slaps show-cause notice on 5 Gujarat Medical Colleges over faculty deficiencies, warns of reducing MBBS seats

Ahmedabad: Taking serious cognizance of the massive faculty deficiencies, the National Medical Commission (NMC) has sent show-cause notices to 5 medical colleges in Gujarat.

According to the Ahmedabad Mirror report, at least five medical colleges and hospitals (MCHs) in Gujarat have received these show-cause notices. Observing severe shortages of medical teachers, tutors, and resident doctors across departments, the Apex Medical Regulator has warned to reduce the MBBS seats in these medical colleges and impose high monetary penalties on these institutes.

The Daily adds that 17 out of 20 departments of GMERS Sola Medical College and Hospital in Ahmedabad have been found deficient by the Commission with respect of the required number of staff.

Also Read: Deficiencies Unaddressed despite show-cause Notices: NMC Warns SKIMS of slashing MBBS seats

In the case of GMERS Gandhinagar, doctors in 18 of 20 departments have less than the required 75% attendance. Ahmedabad Mirror has reported that GMERS Porbandar Medical College and Hospital and GMERS Gotri have also received the show-cause notices.

Meanwhile, the doctors have claimed that the Commission did not take into account several local factors. Gujarat officials said that the basic contention by the doctors is that the NMC has counted biometric attendance for only two months- January and February 2024 for the current evaluation.

Commenting on the matter, a senior official told the Daily, “How can the attendance be counted based on just two months? The doctor may have been present through the year but has taken sanctioned leave in January or February. This may be due to any number of reasons.”

Apart from sanctioned leaves, factors like college transfers, court presence, community work, state holidays, examinations, inspections, university work, presence at health department, seminars and conferences, as well as having to go on medical arrangements for VIPs are also some of the factors that are required to be considered for the absence of doctors from their posts, adds the Daily.

Speaking to Mirror, an official in the Gujarat Health Department explained that NMC wants the deans to be more robust in uploading the reasons for absence of medical teachers or of single punches in the biometric system. The Commission is reportedly stressing on this to ensure that leaves can be processed properly at the central level. The official informed that it appears that NMC wants to ensure that the doctors are on duty and not engaged elsewhere or in private practice during duty hours or ghost faculties are not engaged at the institutes.

The Commission has reportedly given these medical colleges and hospitals another two month’s time to check their attendance. Therefore, the Deans are now cancelling all leaves sought by the doctors.

Indian Medical Colleges have been reeling under a shortage of adequate faculty for a long time. Last year, in an assessment conducted for the academic year 2022-2023, NMC unveiled a disconcerting reality within a majority of medical colleges. Those institutes were riddled with ghost faculties and senior residents, coupled with none meeting the mandated 50% attendance requirement.

Last year, 349 out of the total 654 medical colleges across the country got a show cause notice from the Apex Medical regulator for violations of the Minimum Standard Requirements 2020 including a deficiency in having the required faculty numbers

Notably, NMC has persistently urged medical colleges to adopt the Aadhaar-enabled biometric attendance system (AEBAS). This move is aimed at ensuring transparency and authenticity in faculty attendance.

Medical Dialogues had earlier reported that for the first time, taking note of deficiencies in faculty and clinical material, NMC imposed fines on medical colleges for violating the Maintenance of Standards of Medical Education Regulations, 2023 (MSMER) rules. The Commission slapped a fine of up to Rs 3 lakh on government medical colleges in Tamil Nadu, including the colleges in Dharmapuri, Ramanathapuram, and Nagapattinam. Apart from these colleges, the Commission reportedly has also issued show-cause notices to many other colleges for deficiencies in Aadhaar-based biometric attendance.

Also Read: First time: NMC slaps fine on 3 TN medical colleges for Faculty, Clinical Material Deficiencies

With all this, Medical Colleges have come under extremely tight scrutiny of the National Medical Commission (NMC), as the Apex Medical Regulator has stressed on meeting the faculty as well as infrastructure requirements.

Earlier, medical colleges were facing physical inspections, where a team of assessors would go and visit medical colleges and assess those facilities. This process was widely criticized and accused of being full of bribery and corruption. It was alleged that the assessor would take bribes and approve medical colleges.

However, under the new system, the Apex Medical Regulator is slowly moving online in terms of inspection of medical colleges as well as overseeing the fulfilment of requirements. Although online, with features, like AEBAS and biometric attendance system, it is being difficult for medical colleges to engage ghost faculties.

Speaking to Medical Dialogues, Dr. Aruna Vanikar, the President of NMC UG Medical Education Board (UGMEB) recently informed that NMC has been in talks with the medical colleges across the country on a daily basis to ensure that the medical colleges have been complying with the requirements regarding faculty numbers, biometric attendance, clinical materials and other rules. The process is ongoing and NMC has already reached out to the administrators of around half of the medical colleges.

Also Read: Medical Colleges Under Tight Scrutiny of National Medical Commission

Powered by WPeMatico

Bharat Biotech International Gets CDSCO Panel Nod to Study Mycobacterium Tuberculosis Live Attenuated Vaccine

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved vaccine major Bharat Biotech International’s proposal to conduct the Phase II clinical trial of Mycobacterium Tuberculosis (Live Attenuated) Vaccine to assess the safety and immunogenicity in healthy adolescent and adult populations.

This came after Bharat Biotech International presented a Phase I clinical trial report with 28 days of safety results along with Phase II clinical trial protocol titled “A Phase II, randomized, double-blind trial to assess the Safety and Immunogenicity of MTBVAC (BBV169), with BCG vaccine as a comparator in Healthy adolescent and adult populations”.

However, this approval is subject to the condition that the firm should revise the Exclusion criteria by excluding HIV-positive subjects and Diabetic subjects from the study. In addition, the expert panel suggested performing Molecular-based RT-PCR (Real-Time Reverse Transcription – Polymerase Chain) tests instead of Sputum AFB (Acid- Fast Bacilli) smear tests for diagnosis of TB.

The committee further added that DSMB (Data and Safety Monitoring Board) review should be performed after the day 28 and day 56 follow up and the same should be submitted to CDSCO at the time of Phase III clinical trial application.

MTBVAC is a global public-private project that will be a milestone in the field of vaccinology and in the approach to this highly communicable disease global epidemic with high morbidity and mortality. MTBVAC is one of the most promising vaccine candidates in the current global TB vaccine pipeline. The only currently available TB vaccine, the Bacillus Calmette-Guérin vaccine (BCG), was developed 100 years ago and has limited efficacy in preventing pulmonary TB in adults, who, along with adolescents, are the biggest spreaders of the disease.

At the recent SEC meeting for the Vaccine held on 30th April 2024, the expert panel reviewed the Phase I clinical trial report with 28 days of safety results along with the Phase II clinical trial protocol titled “A Phase II, randomized, double-blind trial to assess the Safety and Immunogenicity of MTBVAC (BBV169), with BCG vaccine as a comparator in Healthy adolescent and adult populations”.

The committee noted the Phase I Clinical trial report results with 28 days of safety results as per the approved protocol.

After detailed deliberation of the Phase II protocol, the committee recommended the grant of permission to conduct Phase II clinical trial as per protocol presented with the following conditions:

1) Exclusion criteria should be revised to mention clearly
(a) HIV-positive subjects will be excluded from the study.
(b) Diabetic subjects will be excluded.
2) Molecular-based RT-PCR test should be performed instead of Sputum AFB smear test for diagnosis of TB.
3) DSMB review should be performed after day 28 and day 56 follow up and the same should be submitted to CDSCO at the time of Phase III clinical trial application.

Accordingly, the expert panel stated that the revised Phase II protocol should be submitted to CDSCO for approval.

Also Read:Alkem Laboratories Gets CDSCO Panel Nod to Study Amoxicillin,Clavulanate Powder for reconstitution into suspension

Powered by WPeMatico

ICMR- National Institute for Research in Reproductive and Child Health invites Applications for PhD Program 2024, all details here

Mumbai- The National Institute for Research in Reproductive and Child Health, Mumbai, (NIRRCH) a premier Institute of the Indian Council of Medical Research (ICMR) has invited applications for admission to PhD program for the 2024 session. Regarding this, ICMR-NIRRCH has released an advertisement detailing the application fees, age limit, selection process, etc of the PhD program.

HOW TO APPLY

Application forms available at the NIRRCH official website should be duly filled and submitted online on or before 22nd May 2024. The hard copy of the application need not be submitted to the Institute. Only filled online applications will be considered.

Also Read: ICMR National Institute for Pathology invites applications for PhD admissions 2022-2023, Check out all details

APPLICATION FEES

1 General and OBC Category: Rs. 300/- plus Transaction Charges as applicable (Non-refundable).

2 SC/ST/PWD and EWS: Exempted from payment of fees.

The application fee is non-refundable and is to be deposited by using net banking facilities (NEFT/IMPS). The applicant’s name should be mentioned in the net banking transaction. Additional charges will be applicable as per the rule of the concerned bank. The Fees will not be accepted through any other mode. Applications without payment of required fees will be considered incomplete and disqualified.

WHO CAN APPLY

1 Candidates who are Indian citizens and have a Post-graduate degree in any branch of Life Sciences (Biochemistry / Biotechnology / Microbiology / Zoology / Bioinformatics /Biophysics etc.) or MBBS/BDS graduates or MD/M.Pharm degree holders from India with at least 55% or equivalent Cumulative Grade Point Average (CGPA) from higher secondary (10+2) onwards for General, OBC and EWS categories and 50% for SC/ST/Person with Disabilities (PWD) candidates in aggregate (or equivalent grade). In case CGPA is not based on a 10-point scale, candidates should provide a statement issued by their respective universities indicating the conversion of CGPA to percentage. Candidates, who have appeared in the academic year 2023-2024 and whose results are awaited, are also eligible to apply. However, if selected, such candidates will have to submit the proof of qualifying marks before joining the Institute. Kindly note that registration for PhD degree at the University of Mumbai will happen only after fulfilling the required eligibility criteria.

2 The candidate should have cleared at least one of the following exams-

I PhD entrance test (PET) conducted by the University of Mumbai in any subjects of Life Sciences/ Applied Biology/ Biochemistry/ Microbiology/ Zoology/ Biophysics/ Bioanalytical Science/ Molecular Biology.

II CSIR-UGC NET (JRF or LS) or GATE (Life Sciences/ Biotechnology with validity up to December 2025) or JRF examination conducted by national agencies such as ICMR/DBT (Life Sciences/Microbiology/Biotechnology/ Biochemistry).

III Valid DST-Inspire fellowship.

IV MH-SET ( Maharashtra State Eligibility Test for Assistant Professor) in Life Sciences.

NIRRCH reserves the right to change the minimum eligibility criteria in case of receipt of a large number of applications. The decision of the Director and Selection Committee will be final and no correspondence will be entertained in this regard. Canvassing in any form and/or bringing in any influence will be treated as disqualification. No travelling allowance shall be provided by the Institute at any stage of the admission process.

Also Read: ICMR invites applications for ACSIR PhD Medical Research programme, All Details Here

AGE LIMIT

The upper age limit is 28 years as on 30th April 2024 for the General and EWS Category. Age relaxation of upto 5 years (33 years) for SC/ST/ PWD/Women candidates and up to 3 years (31 years) for OBC (NonCreamy Layer) candidates will be granted. Reservation will be as per the UGC rules followed by the University of Mumbai.

SELECTION PROCEDURE

The names of the short-listed candidates along with the date and time for the interview will be displayed on the NIRRCH and ICMR websites. The final selection would be based on the performance in the personal interview. The list of PhD guides (who have vacancies for PhD students in their laboratories) and tentative titles of research projects under them would be given to the selected candidates after personal interviews.

Also Read: AFMS, ICMR join hands for collaborative research and training

TIMETABLE FOR SELECTION PROCEDURE

S.NO

PARTICULARS

SCHEDULE

1

Start of online application.

25th April 2024.

2

Last date for submission of online application.

24th May 2024 (Time: 5.30 pm).

3

Announcement of candidates shortlisted for the interview.

Will be intimated on the NIRRCH website.

4

Date of Interview.

Will be intimated on the NIRRCH website.

FELLOWSHIP

The selected candidates, who have passed the JRF examination conducted by CSIR/UGC/ICMR/DBT can avail of fellowship as per the rules of the respective funding agencies. Non-fellowship holders will be provided with an Institutional fellowship of Rs. 8000/- per month only after successful completion of coursework and PhD proposal presentation. It will be for 2 years only and later these students are encouraged to seek fellowship from other funding agencies.

HOSTEL

Women candidates selected for Ph.D. may avail Hostel facility upon request and based on availability.

To view the advertisement, click the link below

https://medicaldialogues.in/pdf_upload/notice-for-phd-admission-2024-236900.pdf

Powered by WPeMatico

80 SR Post Vacancies At AIIMS Raipur: Check Walk In Interview Details Here

Raipur: The All India Institute of Medical Sciences, (AIIMS Raipur) has released vacancies for the Senior Resident post under the Govt. of India Residency Scheme in various departments. The selection will be done on the basis of the Interview.

AIIMS Raipur is an apex healthcare institute, established by the Ministry of Health and Family Welfare, Government of India under the Pradhan Mantri Swasthya Suraksha Yojna (PMSSY) with the aim of correcting regional imbalances in quality tertiary level healthcare in the country and attaining self-sufficiency in graduate and postgraduate medical education and training.

Vacancy Details:

Total no of Vacancies- 80

The Vacancies are in the Department of Anaesthesiology, Anatomy, Biochemistry, Burns & Plastics Surgery, Cardiology, Cardiothoracic Surgery, Clinical Haematology, Community and Family Medicine, Endocrinology and Metabolism, Forensic Medicine and Toxicology, Gastroenterology, General Medicine, Medical Oncology, Microbiology, Neonatology, Nephrology, Neurosurgery, Neurology, Nuclear Medicine, Ophthalmology, Orthopedics, Paediatric, Pathology, Pediatrics Surgery, Physical Medicine and Rehabilitation, Physiology, Radiodiagnosis, Radiotherapy, Surgical Oncology, Transfusion Medicine and Blood Bank, and Trauma & Emergency.

Walk-in-Interview will be conduct on 9th May 2024.

Reporting Time 09:30 AM to 10:30 AM

Note: Candidates reporting after 10:30 AM will not be considered for walk-in-interview.

Venue Committee Room, 1st Floor, Medical College Building, Gate No.05, AIIMS, Tatibandh, G.E. Road, Raipur Chhattisgarh492099

For more details about Qualification, Age, and Pay Allowance, and much more, click on the given link:

What are the Terms & Conditions?

1. A prior intimation will be required from the candidate regarding their confirmation of participation in the Walk-in-Interview. Confirmation should be sent well in advance via e-mail at residentrecruitment@aiimsraipur.edu.in with subject line “Confirmation of participation in the Walk-in-Interview to the post of Senior Resident for the Department of ……………………….. on ………………” with application form PDF. In case of late application submitted the candidate may be entertained only it no application received same department.

2. Only those candidates who have been declared successful in their qualifying degree exam and will be completing their tenure for the same on or before the date of Walk- in-Interview will be eligible.

2. The cases where result of qualifying exam is declare after the date of Walk-in- Interview, their candidature will stand cancelled and no claim for selection on the basis of Interview will be considered.

3. The above vacancies are provisional and subject to variation. The Director, AIIMS, Raipur reserves the right to vary the vacancies including reserved vacancies as per the Govt. of India rules/circulars and requirements. The reservation will be followed as per Government of India Rules.

4. The aspiring applicants satisfying the eligibility criteria in all respects can appear in the interview.

5. The decision of Director, AIIMS Raipur in this regard shall be final and binding. The offer of appointment when made will be provisional and subject to verification of credentials (Educational & Personal) by competent authority. The vacancies are provisional and subject to variation. The Executive Director, AIIMS, Raipur reserves the right to vary the vacancies including reserved vacancies. No correspondence whatsoever would be entertained in this regard.

Also Read:Assistant Professor Post At UPSC In Health Ministry, Apply Now

Powered by WPeMatico